JP2012520085A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520085A5
JP2012520085A5 JP2011554275A JP2011554275A JP2012520085A5 JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5 JP 2011554275 A JP2011554275 A JP 2011554275A JP 2011554275 A JP2011554275 A JP 2011554275A JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5
Authority
JP
Japan
Prior art keywords
sequence
polynucleotide
expression vector
cell
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027365 external-priority patent/WO2010105277A1/en
Publication of JP2012520085A publication Critical patent/JP2012520085A/ja
Publication of JP2012520085A5 publication Critical patent/JP2012520085A5/ja
Pending legal-status Critical Current

Links

JP2011554275A 2009-03-13 2010-03-15 生物活性ｒｎａの送達のための組成物及び方法 Pending JP2012520085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16028809P 2009-03-13 2009-03-13
US16028709P 2009-03-13 2009-03-13
US61/160,287 2009-03-13
US61/160,288 2009-03-13
PCT/US2010/027365 WO2010105277A1 (en) 2009-03-13 2010-03-15 Compositions and methods for the delivery of biologically active rnas

Publications (2)

Publication Number Publication Date
JP2012520085A JP2012520085A (ja) 2012-09-06
JP2012520085A5 true JP2012520085A5 (enExample) 2013-02-21

Family

ID=42728852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554275A Pending JP2012520085A (ja) 2009-03-13 2010-03-15 生物活性ｒｎａの送達のための組成物及び方法

Country Status (8)

Country Link
US (2) US8569065B2 (enExample)
EP (1) EP2406379A4 (enExample)
JP (1) JP2012520085A (enExample)
KR (1) KR20110128345A (enExample)
CN (1) CN102625842A (enExample)
AU (1) AU2010223888A1 (enExample)
CA (1) CA2755245A1 (enExample)
WO (1) WO2010105277A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787156C (en) 2010-01-19 2020-12-29 Northwestern University Synthetic nanostructures for delivery of oligonucleotides
US20130101512A1 (en) * 2010-03-12 2013-04-25 Chad A. Mirkin Crosslinked polynucleotide structure
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9880151B2 (en) * 2011-05-23 2018-01-30 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
HK1203548A1 (en) * 2011-12-23 2015-10-30 Clsn实验室股份有限公司 Compositions and methods for the delivery of biologically active rnas
WO2013101690A1 (en) * 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2906663A1 (en) * 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2810800T3 (es) * 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
US20150232578A1 (en) 2014-02-14 2015-08-20 Symvivo Corporation Hybrid proteins and uses thereof
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015305482B2 (en) 2014-08-19 2021-04-01 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
AU2015328242A1 (en) 2014-10-06 2017-04-27 Exicure, Inc. Anti-TNF compounds
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
AR107469A1 (es) 2016-01-27 2018-05-02 Oncorus Inc Vectores virales oncolíticos y sus usos
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
JP2019515654A (ja) 2016-03-16 2019-06-13 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
BR112019000015A2 (pt) 2016-06-30 2019-04-24 Oncorus, Inc. distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
EP3658165A4 (en) 2017-07-26 2021-09-01 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND THEIR USES
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
EP3818167A4 (en) * 2018-07-05 2022-04-13 The Regents of The University of California COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
EP4034088A4 (en) 2019-09-26 2023-10-11 President and Fellows of Harvard College Minimal arrestin domain containing protein 1 (arrdc1) constructs
US20250263690A1 (en) * 2022-06-15 2025-08-21 Duke University Protein library display systems and methods thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
AU2596400A (en) * 1998-12-31 2000-07-31 Advanced Research And Technology Institute, Inc. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus
WO2002027031A2 (en) * 2000-09-28 2002-04-04 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US20040005593A1 (en) * 2002-03-06 2004-01-08 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of siRNA molecules
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
KR20050084607A (ko) * 2002-09-28 2005-08-26 매사추세츠 인스티튜트 오브 테크놀로지 인플루엔자 치료제
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
WO2007092222A2 (en) * 2006-02-02 2007-08-16 Regenetech, Inc. Method of characterizing a biologically active compound
EP1984399A4 (en) * 2006-02-10 2010-03-03 Univ California TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN100549179C (zh) * 2006-08-07 2009-10-14 汪运山 胃癌靶向AFP基因的siRNAs表达载体及其用途
CA2677568A1 (en) * 2007-02-15 2008-08-21 Dsm Ip Assets B.V. A recombinant host cell for the production of a compound of interest
SG183374A1 (en) * 2010-02-24 2012-09-27 Arrowhead Res Corp Compositions for targeted delivery of sirna

Similar Documents

Publication Publication Date Title
JP2012520085A5 (enExample)
JP2022046503A5 (enExample)
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
CN102558309B (zh) 一对转录激活子样效应因子核酸酶及其编码基因与应用
JP2019524140A5 (enExample)
JP2018532705A5 (enExample)
JP2018528237A5 (enExample)
HRP20230150T1 (hr) Konstrukcija kimernog antigenskog receptora koji cilja cd20 antigen i identifikacija aktivnosti njegovih inženjerskih t-stanica
JP2013507934A5 (enExample)
EP2852407A1 (fr) Cassettes d'expression procaryotes régulées par le stress.
JP2013521789A5 (enExample)
JP2011062217A5 (enExample)
WO2008084115A3 (en) Lactococcus promoters and uses thereof
JP2013530689A5 (enExample)
JP2010539926A5 (enExample)
JP2020523983A5 (enExample)
JP2009528843A5 (enExample)
JP2011520424A5 (enExample)
JP2011505850A5 (enExample)
CN109929865A (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
CN111378047A (zh) 一种提高蛋白表达的融合标签蛋白及其应用
CN102702335A (zh) 重组转录激活子样效应因子、转录激活子样效应因子核酸酶及其编码基因及应用
RU2008153051A (ru) Способ направленной доставки днк в опухолевые и стволовые клетки
CN102753687B (zh) 用于遗传转化藻类的新型启动子